Lawmakers and Advocates Raise Concerns Over FDA Rare Disease Oversight

For members of the inherited retinal disease (IRD) community, navigating the regulatory landscape is a critical part of the journey toward finding treatments and cures. Recently, attention has turned to Washington, where US lawmakers and patient advocates have scrutinized the Food and Drug Administration (FDA) regarding its handling of rare disease therapies.

During a meeting of the US Senate Special Committee on Aging held during Rare Disease Week, participants discussed growing concerns that the FDA's approach to reviewing rare disease treatments has become inconsistent and overly cautious. According to committee chairman Senator Rick Scott, issues such as inconsistent review practices, shifting standards, and redundant or late-appearing data requests can delay patient access to safe and effective therapies. Rare diseases collectively affect more than 30 million people in the United States.

Key Concerns Raised at the Hearing

During the hearing, advocates, clinical experts, and biotech representatives pointed to several challenges within the regulatory process:

  • Inconsistent Reviews: Stakeholders expressed concern that the agency's handling of rare disease therapies lacks predictability.
  • Regulatory Flexibility: Concerns were raised regarding a perceived hesitation to fully utilize regulatory flexibilities and incorporate real-world evidence or patient experience data.
  • Complete Response Letters: Reports noted the issuance of nearly two dozen complete response letters for rare disease treatments since the start of 2025.
  • Advisory Panels: The panel recommended that the FDA reinstate its practice of holding advisory committee meetings for drugs under review.

Meanwhile, the FDA has defended its record, stating via pharmaphorum reporting that it must balance the urgent need for speed and new treatments—particularly for conditions with no existing options—with its responsibility to ensure that therapies are supported by robust, high-quality data.

What This Means for Patients and Families

For patients and families affected by rare conditions like IRDs, the regulatory pathway dictates how quickly scientific innovations move from the laboratory to clinical availability. Delays or friction in the approval process directly impact when—or if—treatments reach those in desperate need. While regulatory rigor is essential for safety, the community continues to advocate for a system that recognizes the unique challenges of developing therapies for small patient populations.

As policy discussions continue, stakeholders across the rare disease landscape will monitor how regulatory agencies balance evidentiary standards with the pressing demand for accessible, breakthrough treatments.